Viking Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Viking Therapeutics, Inc. (VKTX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $131.00 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-07-29
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $131.00M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $101.00M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $114.00M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $75.00M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $131.00M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $101.00M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $114.00M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $75.00M 10-Q · filed 2025-10-23 | |
| 2025-06-30 | $76.61M 10-Q · filed 2025-07-23 | |
| 2025-03-31 | $66.39M 10-Q · filed 2025-04-24 | |
| 2024-12-31 | $141.30M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $255.37M 10-Q · filed 2024-10-23 | |
| 2024-06-30 | $222.82M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | $401.00M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $62.21M 10-K · filed 2026-02-11 | $62.21B 10-K · filed 2024-02-07 |
| 2023-09-30 | $23.33B 10-Q · filed 2023-10-25 | |
| 2023-06-30 | $49.59B 10-Q · filed 2023-07-26 | |
| 2023-03-31 | $60.33B 10-Q · filed 2023-04-26 | |
| 2022-12-31 | $20.52M 10-K · filed 2026-02-11 | $20.52B 10-K · filed 2023-02-10 |
| 2022-09-30 | $1.13M 10-Q · filed 2022-10-26 | |
| 2022-06-30 | $1.28M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $1.37M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $2.88M 10-K · filed 2025-02-26 | $2.88B 10-K · filed 2022-02-09 |
| 2021-09-30 | $5.57M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $4.97M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $5.95M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $389.00M 10-K · filed 2024-02-07 | $4.58B 10-K · filed 2021-02-17 |
| 2020-09-30 | $4.86M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $7.36M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $3.33M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $8.64B 10-K · filed 2021-02-17 | |
| 2019-09-30 | $6.67M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $9.70M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $13.71M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $8.60B 10-K · filed 2020-02-26 | |
| 2018-09-30 | $27.58M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $11.83M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $3.59M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $3.35B 10-K · filed 2019-03-13 | $3.35M 10-K · filed 2018-03-07 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-21 | |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $0.00 10-K · filed 2016-03-08 | |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |